Wajd Alkabbani

430 total citations
25 papers, 243 citations indexed

About

Wajd Alkabbani is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Wajd Alkabbani has authored 25 papers receiving a total of 243 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Molecular Biology and 5 papers in Surgery. Recurrent topics in Wajd Alkabbani's work include Diabetes Treatment and Management (17 papers), Diabetes Management and Research (7 papers) and Metabolism, Diabetes, and Cancer (7 papers). Wajd Alkabbani is often cited by papers focused on Diabetes Treatment and Management (17 papers), Diabetes Management and Research (7 papers) and Metabolism, Diabetes, and Cancer (7 papers). Wajd Alkabbani collaborates with scholars based in Canada, United States and India. Wajd Alkabbani's co-authors include John‐Michael Gamble, Kelvin Kuan Huei Ng, Baiju R. Shah, Dean T. Eurich, Arsène Zongo, Mhd Wasem Alsabbagh, Ruth Ann Marrie, Jasjeet K. Minhas‐Sandhu, Colleen J. Maxwell and Iliana C. Lega and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Internal Medicine and Diabetes Care.

In The Last Decade

Wajd Alkabbani

20 papers receiving 239 citations

Peers

Wajd Alkabbani
Sheriza Baksh United States
Ramin Rezaeianzadeh Canada
Jingyue Huang China
Esther Artime Spain
Kyaw Soe United States
H. Karl Greenblatt United States
Nadia Khan Canada
Helen Tesfaye United States
Kota Vidyasagar India
Federica Galimberti Italy
Sheriza Baksh United States
Wajd Alkabbani
Citations per year, relative to Wajd Alkabbani Wajd Alkabbani (= 1×) peers Sheriza Baksh

Countries citing papers authored by Wajd Alkabbani

Since Specialization
Citations

This map shows the geographic impact of Wajd Alkabbani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wajd Alkabbani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wajd Alkabbani more than expected).

Fields of papers citing papers by Wajd Alkabbani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wajd Alkabbani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wajd Alkabbani. The network helps show where Wajd Alkabbani may publish in the future.

Co-authorship network of co-authors of Wajd Alkabbani

This figure shows the co-authorship network connecting the top 25 collaborators of Wajd Alkabbani. A scholar is included among the top collaborators of Wajd Alkabbani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wajd Alkabbani. Wajd Alkabbani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Crisafulli, Salvatore, Wajd Alkabbani, Julie M. Paik, et al.. (2025). Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes. Annals of Internal Medicine. 179(1). 1–11.
2.
Alkabbani, Wajd, Sara J. Cromer, & Elisabetta Patorno. (2025). Neovascular Age-Related Macular Degeneration and GLP-1 RAs. JAMA Ophthalmology. 143(12). 1077–1077.
3.
Alkabbani, Wajd, Baiju R. Shah, Moira K. Kapral, et al.. (2025). Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study. Alzheimer s Research & Therapy. 17(1). 269–269.
4.
Alkabbani, Wajd, Sara J. Cromer, Dae Hyun Kim, et al.. (2025). Overall Uptake and Racial, Ethnic, and Socioeconomic Disparities in the Use of Continuous Glucose Monitoring Devices Among Insulin-Treated Older Adults With Type 2 Diabetes. Diabetes Care. 48(8). 1377–1385. 1 indexed citations
5.
Chhabra, Manik, Caitlin Carter, Wajd Alkabbani, et al.. (2024). Prevalence of Potentially Inappropriate Medications in Older Adults with Cognitive Impairment or Dementia Attending Memory Clinics: A Systematic Review and Meta-Analysis. Journal of Alzheimer s Disease. 101(4). 1107–1120. 2 indexed citations
6.
Carter, Caitlin, Wajd Alkabbani, Manik Chhabra, et al.. (2024). Use of Potentially Inappropriate Medications among Older Adults with Dementia or Cognitive Impairment Attending Memory Clinics: A Protocol for a Systematic Review and Meta-Analysis. SHILAP Revista de lepidopterología. 9(1). 83–88. 1 indexed citations
7.
Alkabbani, Wajd, Sara J. Cromer, Julie M. Paik, et al.. (2024). Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study. BMJ. 387. e080340–e080340. 17 indexed citations
8.
Alkabbani, Wajd, Baiju R. Shah, Arsène Zongo, et al.. (2023). Post‐initiation predictors of discontinuation of the sodium‐glucose cotransporter‐2 inhibitors: A comparative cohort study from the United Kingdom. Diabetes Obesity and Metabolism. 25(12). 3490–3500. 5 indexed citations
9.
Maxwell, Colleen J., Wajd Alkabbani, Cecilia A. Cotton, et al.. (2023). Psychotropic, Anticonvulsant, and Opioid Use in Assisted Living Residents Before and During the COVID-19 Pandemic. Journal of the American Medical Directors Association. 25(1). 121–129. 6 indexed citations
10.
Alkabbani, Wajd, Colleen J. Maxwell, Ruth Ann Marrie, et al.. (2023). Insulin Use in Type 2 Diabetes and the Risk of Dementia: A Comparative Population-Based Cohort Study. Diabetes Care. 46(8). 1492–1500. 7 indexed citations
11.
Alkabbani, Wajd, et al.. (2022). Peak performance: Putting type 1 diabetes management recommendations for athletes to the test. PubMed. 7. 100011–100011.
12.
Alkabbani, Wajd & John‐Michael Gamble. (2022). Prescribing Trends of the Sodium–Glucose Cotransporter-2 Inhibitors Among Different Physician Specialties in Canada (2015–2021). Canadian Journal of Diabetes. 47(2). 153–161. 2 indexed citations
13.
Alkabbani, Wajd, Arsène Zongo, Jasjeet K. Minhas‐Sandhu, et al.. (2022). Five comparative cohorts to assess the risk of genital tract infections associated with sodium‐glucose cotransporter‐2 inhibitors initiation in type 2 diabetes mellitus. Diabetic Medicine. 39(8). e14858–e14858. 7 indexed citations
14.
Ng, Kelvin Kuan Huei, et al.. (2021). Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. Therapeutic Advances in Drug Safety. 12. 586531086–586531086. 56 indexed citations
15.
Alkabbani, Wajd, Arsène Zongo, Jasjeet K. Minhas‐Sandhu, et al.. (2021). Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score–matched Population-based Cohort Study. Canadian Journal of Diabetes. 46(4). 392–403.e13. 18 indexed citations
16.
Alkabbani, Wajd & John‐Michael Gamble. (2021). Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date. Drug Design Development and Therapy. Volume 15. 3057–3069. 11 indexed citations
17.
Alkabbani, Wajd, John‐Michael Gamble, Dean T. Eurich, et al.. (2021). Risk of hospitalization and death associated with sodium glucose cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs. Diabetes & Metabolism. 48(2). 101305–101305. 4 indexed citations
18.
Alkabbani, Wajd & John‐Michael Gamble. (2021). Active‐comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors. British Journal of Clinical Pharmacology. 89(2). 431–439. 22 indexed citations
19.
Ng, Kelvin Kuan Huei, et al.. (2020). The association of sodium‐glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews. Endocrinology Diabetes & Metabolism. 3(3). e00145–e00145. 26 indexed citations
20.
Alkabbani, Wajd, Ruth Ann Marrie, Shawn Bugden, et al.. (2018). Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study. CMAJ Open. 6(4). E637–E642. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sheriza Baksh Breakdown of academic impact, for papers by Ramin Rezaeianzadeh Breakdown of academic impact, for papers by Jingyue Huang Breakdown of academic impact, for papers by Esther Artime Breakdown of academic impact, for papers by Kyaw Soe Breakdown of academic impact, for papers by H. Karl Greenblatt Breakdown of academic impact, for papers by Nadia Khan Breakdown of academic impact, for papers by Helen Tesfaye Breakdown of academic impact, for papers by Kota Vidyasagar Breakdown of academic impact, for papers by Federica Galimberti
Rankless by CCL
2026